Jody A. Charnow

Editor https://www.cancertherapyadvisor.com

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

Black Men with Low-Risk Prostate Cancer Produce Less PSA

ESMO 2022

Novel Hormonal Therapies for nmCRPC Underused, Data Show

Jody A. Charnow

September 20, 2022

Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.

Doctor escorting senior man down the hall

ESMO 2022

Survival Improving in Metastatic Castration-Sensitive Prostate Cancer Population

Jody A. Charnow

September 16, 2022

The increase in survival for patients with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.

Prostate Cancer

Metastasis-Directed Therapy for Prostate Cancer Found Beneficial Long-Term

Jody A. Charnow

September 7, 2022

MDT significantly prolonged progression-free survival, with the largest effect observed among patients with tumors harboring high-risk genetic mutations.

Bladder Cancer

Tislelizumab Shows Promising Antitumor Benefits in Advanced Bladder Cancer

Jody A. Charnow

September 7, 2022

Adding tislelizumab to gemcitabine/cisplatin improved outcomes in patients with locally advanced or metastatic bladder cancer.

Bladder Cancer

More Advanced Bladder Cancers Encountered After COVID-19 Pandemic

Jody A. Charnow

September 6, 2022

Investigators hypothesize that patients presented later to their health care providers during the first year of the pandemic.

For Prostate Cancer Patients, Doctors Best Source of Info

General Oncology

Chronic Kidney Disease Is a Cancer Risk Factor, Study Finds

Jody A. Charnow

September 1, 2022

Cancer developed in 22% of patients diagnosed with chronic kidney disease at ages 50 to 80 years, which is higher than the lifetime risk of cancer in the general population, according to investigators.

Bladder Cancer

Opioid Use in Advanced Urothelial Carcinoma Quantified

Jody A. Charnow

August 10, 2022

Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma than among matched control individuals, a study showed.

Urologic Cancers

Minimally Invasive, Open Surgery for Adrenocortical Tumors Offer Similar Outcomes

Jody A. Charnow

July 20, 2022

A recent study revealed that minimally invasive and open adrenalectomy are associated with similar rates of positive surgical margins and overall survival for larger tumors.

Renal Cell Carcinoma

Kidney Failure Risk Higher After Kidney Cancer Surgery

Jody A. Charnow

July 18, 2022

Investigators report a cumulative 10-year incidence of end-stage kidney disease of 2.5% among patients who undergo surgery for renal cell carcinoma (RCC), which is 10 times higher than in patients without RCC.

Nerve-Sparing Prostate Surgery illustration

Prostate Cancer

NeuroSAFE Ups Odds of Nerve-Sparing Prostate Cancer Surgery

Jody A. Charnow

July 13, 2022

Intraoperative pathologic assessment of tissue adjacent to the neurovascular bundles after removal of the prostate increases the likelihood of nerve-sparing surgery.

Next post in Prostate Cancer